{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-054483","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.395961+00:00","generated_at":"2026-06-28T13:03:16.364588+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Treace Medical Q3 revenue $21.6M (+52% YoY); net loss ($6.4M); FY21 guidance reaffirmed $90-95M","bullets":["Revenue $21.6M, up 52% YoY from $14.3M; gross margin 80.4% (+80 bps).","Net loss ($6.4M) or ($0.12) per share vs ($2.8M) or ($0.08) in Q3 2020.","Full-year 2021 revenue guidance reaffirmed at $90M-$95M (57-65% growth).","Cash $109.5M; launched Adductoplasty System; appointed two new board members.","ALIGN3D study showed 0.9% recurrence at 12 months; first Mini3D patient treated."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-054483","json":"https://secwatch.observer/filing/0001564590-21-054483.json","markdown":"https://secwatch.observer/filing/0001564590-21-054483.md","text":"https://secwatch.observer/filing/0001564590-21-054483.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000156459021054483/0001564590-21-054483-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000156459021054483/tmci-8k_20211104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:03:16.364588+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}